EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

Daniel L Hertz, Markus Joerger, Yung-Jue Bang, Ron H Mathijssen, Caicun Zhou, Li Zhang, David Gandara, Michael Stahl, Bradley J Monk, Ulrich Jaehde, Jan H Beumer

European Journal of Cancer · 2024-05 · 202 · 114024

DOI: 10.1016/j.ejca.2024.114024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2024-05. Verfasst von Daniel L Hertz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPaclitaxelDrug MonitoringRetrospective StudiesProspective Studies

Stichwörter der Autor:innen

Clinical benefitDose adjustmentExposurePaclitaxelPlasma concentrationsResponseTDMTherapeutic drug monitoringTime above thresholdToxicity

Substanzen

Paclitaxel

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
  • Department of Medical Oncology & Hematology, Cantonal Hospital, St. Gallen, Switzerland. Electronic address: markus.joerger@kssg.ch.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Hertz, D. L., Joerger, M., Bang, Y. J., Mathijssen, R. H., Zhou, C., Zhang, L., Gandara, D., Stahl, M., Monk, B. J., Jaehde, U., & Beumer, J. H. (2024). Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. European Journal of Cancer, 202, 114024. https://doi.org/10.1016/j.ejca.2024.114024

Vancouver

Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, et al. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. European Journal of Cancer. 2024;202:114024. doi:10.1016/j.ejca.2024.114024

BibTeX
@article{Hertz2024,
  author = {Hertz, Daniel L and Joerger, Markus and Bang, Yung-Jue and Mathijssen, Ron H and Zhou, Caicun and Zhang, Li and Gandara, David and Stahl, Michael and Monk, Bradley J and Jaehde, Ulrich and Beumer, Jan H},
  title = {Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {202},
  pages = {114024},
  doi = {10.1016/j.ejca.2024.114024}
}
Kostenlos starten →